O Shaughnessy Asset Management LLC Has $22.71 Million Holdings in Cencora, Inc. $COR

O Shaughnessy Asset Management LLC cut its stake in shares of Cencora, Inc. (NYSE:COR) by 5.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 67,242 shares of the company’s stock after selling 3,846 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Cencora were worth $22,711,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Oakworth Capital Inc. acquired a new position in Cencora during the 4th quarter valued at about $26,000. Elyxium Wealth LLC purchased a new stake in shares of Cencora in the fourth quarter worth approximately $27,000. Archer Investment Corp lifted its holdings in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares in the last quarter. Optima Capital LLC bought a new position in shares of Cencora in the fourth quarter valued at approximately $31,000. Finally, Basepoint Wealth LLC purchased a new position in shares of Cencora during the fourth quarter valued at approximately $32,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of NYSE:COR opened at $274.04 on Tuesday. The firm has a market capitalization of $53.32 billion, a PE ratio of 21.02, a P/E/G ratio of 1.48 and a beta of 0.59. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The company has a 50-day moving average price of $291.82 and a two-hundred day moving average price of $329.69. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same period in the previous year, the firm earned $4.42 EPS. The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts forecast that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its board has authorized a stock repurchase program on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its stock is undervalued.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Robert W. Baird dropped their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. UBS Group increased their target price on shares of Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Wells Fargo & Company dropped their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Finally, Evercore set a $360.00 price objective on shares of Cencora in a research report on Wednesday, April 8th. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.